**Supplementary Table 1: Screening Criteria Used to Identify Relevant Articles for Review. FDA; Food and Drug Administration, CGRP; calcitonin gene related peptide, mAbs; monoclonal antibodies.**

|  |  |  |
| --- | --- | --- |
| **Study Parameter** | **Inclusion Criteria** | **Exclusion Criteria** |
| **Study Treatment** | * FDA-approved CGRP-Targeting Therapeutic (as of February 2024) * Gepants: Ubrogepant, Rimegepant, Atogepant, Zavegepant * mAbs: Fremanezumab, Erenumab, Galcanezumab, Eptinezumab | * Non-FDA approved CGRP-targeting therapeutics. * Non-CGRP-Targeting therapeutics |
| **Source of Funding** | * Industry-sponsored | * Non-Industry sponsored |
| **Trial Design / Publication Type** | * Phase II or III Clinical Trial with efficacy outcomes | * Studies that did not assess efficacy (studies that only reported safety or tolerability outcomes) * Extension-studies * *Post-hoc* or secondary analysis of Phase II/III Clinical Trials |
| **Study Location** | * Studies Conducted at sites in the United States | * Studies conducted at sites outside the United States |
| **Study Participants** | * Adult participants (18+) | * Pediatric participants (<18) or mixed adult/pediatric study participants |
| **Publication Language** | * English Publications | * Non-English Publications |